Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for its lead oncology program, casdatifan, and to outline near-term plans for ...

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory ...

An icon in the shape of a lightning bolt. Impact Link While Arcus CEO Edrizio De La Cruz was studying at the University of Pennsylvania's Wharton Business School, he was also trying to come up with ...

Shares of cancer drug developer Arcus Biosciences skyrocketed as much as 99% in Thursday trading after Bloomberg reported biotech firm Gilead may buy a stake in the company. Alphabet owns the largest ...

Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcinoma (ccRCC) This is the second ...

Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. The third dose-escalation cohort (100mg) of ARC-20 for AB521, a ...

At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing ...

Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...

Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical ...